7 TIMES SQUARE, NEW YORK, NY
Reports Full Year 2025 Financial Results and Provides Corporate Update
SELLAS Life Sciences Secures $42.6 Million from Warrant Exercises
SELLAS Life Sciences Reports $71.8M Cash Position and $26.5M from Warrants
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
News, Material Contracts
Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds
Financial Results, Press Release
FY 2025
Q3
Q2
Q1
FY 2024
S-3ASR
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload